Pascalina Chanda-Kapata

Pascalina Chanda-Kapata

Auto-generated profile, based on publicly available information

Pascalina Chanda-Kapata

Tropical Health, Lusaka, Zambia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2009 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
RPRichard J. Pearce
Richard J. Pearce
HPHirva Pota
Hirva Pota
MEMarie-Solange B. Evehe
Marie-Solange B. Evehe
EBEl-Hadj Bâ
El-Hadj Bâ
Ghyslain Mombo-NgomaGhyslain Mombo-Ngoma
Ghyslain Mombo-Ngoma
CRCally Roper
Cally Roper
Although the molecular basis of resistance to a number of common antimalarial drugs is well known, a geographic description of the emergence and dispersal of resistance mutations across Africa has not been attempted. To that end we have characterised the evolutionary origins of antifolate resistance mutations in the dihydropteroate synthase (dhps) gene and mapped their contemporary distribution. We used microsatellite polymorphism flanking the dhps gene to determine which resistance alleles shared common ancestry and found five major lineages each of which had a unique geographical distribution. The extent to which allelic lineages were shared among 20 African Plasmodium falciparum populations revealed five major geographical groupings. Resistance lineages were common to all sites within these regions. The most marked differentiation was between east and west African P. falciparum, in which resistance alleles were not only of different ancestry but also carried different resistance mutations. Resistant dhps has emerged independently in multiple sites in Africa during the past 10–20 years. Our data show the molecular basis of resistance differs between east and west Africa, which is likely to translate into differing antifolate sensitivity. We have also demonstrated that the dispersal patterns of resistance lineages give unique insights into recent parasite migration patterns.

1 April 2020 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
NKNathan Kapata
Nathan Kapata
CIChikwe Ihekweazu
Chikwe Ihekweazu
FNFrancine Ntoumi
Francine Ntoumi
TRTajudeen Raji
Tajudeen Raji
PCPascalina Chanda-Kapata
Pascalina Chanda-Kapata
AZAlimuddin Zumla
Alimuddin Zumla

15 January 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NKNathan Kapata
Nathan Kapata
PCPascalina Chanda-Kapata
Pascalina Chanda-Kapata
WNWilliam Ngosa
William Ngosa
MMMine Metitiri
Mine Metitiri
EKEveline Klinkenberg
Eveline Klinkenberg
MGMartin P. Grobusch
Martin P. Grobusch
Tuberculosis in Zambia is a major public health problem, however the country does not have reliable baseline data on the TB prevalence for impact measurement; therefore it was among the priority countries identified by the World Health Organization to conduct a national TB prevalence survey To estimate the prevalence of tuberculosis among the adult Zambian population aged 15 years and above, in 2013–2014. A cross-sectional population-based survey was conducted in 66 clusters across all the 10 provinces of Zambia. Eligible participants aged 15 years and above were screened for TB symptoms, had a chest x-ray (CXR) performed and were offered an HIV test. Participants with TB symptoms and/or CXR abnormality underwent an in-depth interview and submitted one spot- and one morning sputum sample for smear microscopy and liquid culture. Digital data collection methods were used throughout the process. Of the 98,458 individuals who were enumerated, 54,830 (55.7%) were eligible to participate, and 46,099 (84.1%) participated. Of those who participated, 45,633/46,099 (99%) were screened by both symptom assessment and chest x-ray, while 466/46,099 (1.01%) were screened by interview only. 6,708 (14.6%) were eligible to submit sputum and 6,154/6,708 (91.7%) of them submitted at least one specimen for examination. MTB cases identified were 265/6,123 (4.3%). The estimated national adult prevalence of smear, culture and bacteriologically confirmed TB was 319/100,000 (232-406/100,000); 568/100,000 (440-697/100,000); and 638/100,000 (502-774/100,000) population, respectively. The risk of having TB was five times higher in the HIV positive than HIV negative individuals. The TB prevalence for all forms was estimated to be 455 /100,000 population for all age groups. The prevalence of tuberculosis in Zambia was higher than previously estimated. Innovative approaches are required to accelerate the control of TB.

12 October 2009 in Malaria Journal
Verified
Journal Article
Open access
PDF file
Karen I BarnesKaren I Barnes
Karen I Barnes
PCPascalina Chanda
Pascalina Chanda
GBGebre Ab Barnabas
Gebre Ab Barnabas
Malaria is one of the most significant causes of morbidity and mortality worldwide. Every year, nearly one million deaths result from malaria infection. Malaria can be controlled in endemic countries by using artemisinin-based combination therapy (ACT) in combination with indoor residual spraying (IRS) and insecticide-treated nets (ITNs). At least 40 malaria-endemic countries in sub-Saharan Africa now recommend the use of ACT as first-line treatment for uncomplicated falciparum malaria as a cornerstone of their malaria case management. The scaling up of malaria control strategies in Zambia has dramatically reduced the burden of malaria. Zambia was the first African country to adopt artemether/lumefantrine (AL; Coartem®) as first-line therapy in national malaria treatment guidelines in 2002. Further, the vector control with IRS and ITNs was also scaled up. By 2008, the rates of in-patient malaria cases and deaths decreased by 61% and 66%, respectively, compared with the 2001-2002 reference period.

9 June 2011 in Malaria Journal
Verified
Journal Article
Open access
PDF file
PCPascalina Chanda
Pascalina Chanda
BHBusiku Hamainza
Busiku Hamainza
HMHawela B Moonga
Hawela B Moonga
VCVictor Chalwe
Victor Chalwe
FPFranco Pagnoni
Franco Pagnoni
Access to prompt and effective treatment is a cornerstone of the current malaria control strategy. Delays in starting appropriate treatment is a major contributor to malaria mortality. WHO recommends home management of malaria using artemisininbased combination therapy (ACT) and Rapid Diagnostic tests (RDTs) as one of the strategies for improving access to prompt and efective malaria case management.

25 March 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
PCPascalina Chanda-Kapata
Pascalina Chanda-Kapata
FNFrancine Ntoumi
Francine Ntoumi
NKNathan Kapata
Nathan Kapata
PLPatrick Lungu
Patrick Lungu
LMLuchenga Adam Mucheleng'ANga
Luchenga Adam Mucheleng'ANga
JNJean B. Nachega
Jean B. Nachega
The unprecedented and ongoing COVID-19 pandemic has exposed weaknesses in African countries’ health systems. The impact of shifted focus on COVID-19 for the past 2 years on routine health services, especially those for the epidemics of Tuberculosis, HIV/AIDS and Malaria, have been dramatic in both quantity and quality. In this article, we reflect on the COVID-19 related disruptions on the Tuberculosis, HIV/AIDS and Malaria routine health services across Africa. The COVID-19 pandemic resulted in disruptions of routine health services and diversion of already limited available resources in sub-Saharan Africa. As a result, disease programs like TB, malaria and HIV have recorded gaps in prevention and treatment with the prospects of reversing gains made towards meeting global targets. The extent of the disruption is yet to be fully quantified at country level as most data available is from modelling estimates before and during the pandemic. Accurate country-level data is required to convince donors and governments to invest more into revamping these health services and help prepare for managing future pandemics without disruption of routine services. Increasing government expenditure on health is a critical part of Africa's economic policy. Strengthening health systems at various levels to overcome the negative impacts of COVID-19, and preparing for future epidemics will require strong visionary political leadership. Innovations in service delivery and technological adaptations are required as countries aim to limit disruptions to routine services.